fidarestat has been researched along with tolrestat in 6 studies
| Studies (fidarestat) | Trials (fidarestat) | Recent Studies (post-2010) (fidarestat) | Studies (tolrestat) | Trials (tolrestat) | Recent Studies (post-2010) (tolrestat) |
|---|---|---|---|---|---|
| 97 | 3 | 33 | 198 | 25 | 14 |
| Protein | Taxonomy | fidarestat (IC50) | tolrestat (IC50) |
|---|---|---|---|
| Aldo-keto reductase family 1 member B10 | Homo sapiens (human) | 0.0244 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 0.2689 | |
| Aldo-keto reductase family 1 member A1 | Homo sapiens (human) | 1.1533 | |
| Aldo-keto reductase family 1 member B1 | Homo sapiens (human) | 0.2303 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.096 | |
| Aldo-keto reductase family 1 member B1 | Bos taurus (cattle) | 0.043 | |
| Aldo-keto reductase family 1 member A1 | Sus scrofa (pig) | 1.365 | |
| Aldo-keto reductase family 1 member A1 | Rattus norvegicus (Norway rat) | 1.21 | |
| Aldo-keto reductase family 1 member B1 | Sus scrofa (pig) | 0.0225 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.03 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Demopoulos, VJ; Nicolaou, I | 1 |
| Dhagat, U; El-Kabbani, O; Endo, S; Hara, A | 1 |
| Kato, N; Oka, M | 1 |
| Ling, B; Liu, C; Liu, Y; Suo, Y; Wang, Z; Yu, Z; Zhang, R | 1 |
| Cousido-Siah, A; Farrés, J; Mitschler, A; Parés, X; Podjarny, A; Ruiz, FX | 1 |
| Chen, S; Chen, Y; Hu, X; Li, Q; Li, Z; Wang, Z; Xie, W; Zhai, J; Zhang, H; Zhang, L; Zhao, Y; Zheng, X | 1 |
1 review(s) available for fidarestat and tolrestat
| Article | Year |
|---|---|
Aldose reductase inhibitors.
Topics: Aldehyde Reductase; Binding Sites; Clinical Trials as Topic; Crystallography, X-Ray; Diabetic Neuropathies; Enzyme Inhibitors; Humans; Imidazoles; Imidazolidines; Naphthalenes; Quinazolines | 2001 |
5 other study(ies) available for fidarestat and tolrestat
| Article | Year |
|---|---|
Substituted pyrrol-1-ylacetic acids that combine aldose reductase enzyme inhibitory activity and ability to prevent the nonenzymatic irreversible modification of proteins from monosaccharides.
Topics: Acetates; Aldehyde Reductase; Animals; Diabetes Mellitus; Enzyme Inhibitors; Female; Fructose; Male; Monosaccharides; Oxidation-Reduction; Proteins; Pyrroles; Rats; Rats, Inbred F344; Serum Albumin; Structure-Activity Relationship | 2003 |
Inhibition of 3(17)alpha-hydroxysteroid dehydrogenase (AKR1C21) by aldose reductase inhibitors.
Topics: 3-Hydroxysteroid Dehydrogenases; Aldehyde Reductase; Animals; Binding Sites; Enzyme Inhibitors; Mice; Models, Molecular; Protein Binding; Substrate Specificity | 2008 |
Docking and molecular dynamics studies toward the binding of new natural phenolic marine inhibitors and aldose reductase.
Topics: Aldehyde Reductase; Enzyme Inhibitors; Hydrogen Bonding; Imidazolidines; Molecular Dynamics Simulation; Naphthalenes; Protein Structure, Secondary; Rhodanine; Thiazolidines | 2009 |
X-ray structure of the V301L aldo-keto reductase 1B10 complexed with NADP(+) and the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity.
Topics: Alcohol Oxidoreductases; Aldehyde Reductase; Aldo-Keto Reductases; Binding Sites; Crystallography, X-Ray; Enzyme Inhibitors; Imidazolidines; Inhibitory Concentration 50; NADP; Naphthalenes | 2013 |
Inhibitor selectivity between aldo-keto reductase superfamily members AKR1B10 and AKR1B1: role of Trp112 (Trp111).
Topics: Aldehyde Reductase; Aldo-Keto Reductases; Benzothiazoles; Catalytic Domain; Crystallography, X-Ray; Enzyme Inhibitors; Flufenamic Acid; Hydrogen Bonding; Imidazolidines; Models, Molecular; Naphthalenes; Oleanolic Acid; Phthalazines; Protein Binding; Protein Structure, Secondary; Rhodanine; Structural Homology, Protein; Thiazolidines; Tryptophan | 2013 |